On 25 June 2022, the national launch meeting of the "Hepatitis B Clinical Cure Starlight Project" (the "STARHB Project"), initiated by the China Liver Health and co-led by Professor Chen Yueyue of Beijing Youan Hospital of Capital Medical University and Professor Gao Zhiliang of the Third Affiliated Hospital of Sun Yat-sen University, was successfully launched online.
It is reported that the "STARHB Project" is the first large-scale public welfare project in China for inactive HBeAg-negative chronic HBV-infected patients (referred to as IHC population), aiming to help more chronic hepatitis B virus-infected patients to obtain clinical cure, and strive to achieve the Health China 2030 Action and the World Health Organization 2030 elimination of viral The aim is to help more people with chronic hepatitis B virus infection to get a clinical cure and to achieve the goal of the Healthy China 2030 initiative and the World Health Organization's 2030 target of eliminating the public health risk of viral hepatitis.
Experts attending the project At the kick-off meeting, Prof. He Qinghua, First Inspector of the National Health Commission, Prof. Zhuang Hui of Peking University Medical School, Prof. Wei Lai, Vice President of Tsinghua Changgeng Hospital, Prof. Ma Yingmin, President of Beijing Youan Hospital, Prof. Li Jie of Peking University Medical School, Prof. Xu Xiaoyuan of Peking University First Hospital, Prof. Nan Yuemin of the Third Hospital of Hebei Medical University, Prof. Chen Yuexin of Beijing Youan Hospital, Prof. Gao Zhiliang of the Third Hospital of Sun Yat-sen University, Prof. Zheng Sujun of Beijing Youan Hospital, Prof. Lin Bingliang of the Third Hospital of Sun Yat-sen University and other renowned experts in the field of liver disease infection. The conference was simulcast live on the public platforms of Liver & Gallbladder, Rainy Liver Lin, Journal of Clinical Hepatobiliary Diseases and the China Liver Health respectively. Over 20,000 doctors and patients from all over China participated in the online interaction, and the conference was warmly received and widely watched. We have about 30 million people with IHC Significantly higher risk of liver cancer
He Qinghua, First Class Inspector, National Health Commission He Qinghua, a first-class inspector of the National Health Commission, pointed out that viral hepatitis is a major public health problem that seriously endangers the health of our people, bringing about a huge socio-economic impact and a heavy financial burden to patients and their families. China has always attached great importance to the prevention and treatment of viral hepatitis and promoted the detection and treatment of hepatitis B in all elements, achieving great results and gaining global recognition. According to statistics, there are about 86 million people with chronic hepatitis B virus infection in China. Chronic hepatitis B virus infection rarely cures itself without intervention, and the disease usually progresses insidiously and slowly, so it is easily ignored by infected people, making the risk of progression to liver cirrhosis and liver cancer increase. The "Hepatitis B Clinical Cure Starlight Project" is a nationwide study focusing on the HBeAg-negative chronic HBV-infected population, which has great social and scientific significance.
Academician Zhuang Hui, Peking University School of Medicine Academician Zhuang Hui of Peking University School of Medicine said that there are about 30 million cases of IHC population in China and recent studies have found that about 50% of these patients have significant liver histopathological changes and are at significantly higher risk of developing liver cancer than the general population, thus necessitating the need for relevant research. The "STARHB Project" is a study on the antiviral treatment and long-term observation of inactive HBeAg-negative chronic HBV infected patients and is currently the largest study of chronic HBV infection in the world.
Professor Zheng Sujun, Beijing Youan Hospital, Capital Medical University Professor Zheng Sujun of Beijing You'an Hospital, Capital Medical University, said that IHC is a large group of hepatitis B infected people, often neglected because of the insidious progression of the disease, but in fact the risk of progression to liver cancer in the Chinese IHC population is 4.6 times higher than that in the healthy population, and the risk of liver cancer in the Asian IHC population is 10 times higher than that in the European and American populations. Patients with IHC have a higher chance of obtaining a clinical cure Over the past 10 years, Chinese experts have been at the forefront of the world's quest for a clinical cure for chronic hepatitis B. They have achieved remarkable results in a number of large-scale clinical practices.
Professor Gao Zhiliang, The Third Hospital of Sun Yat-sen University Professor Gao Zhiliang of the Third Hospital of Sun Yat-sen University pointed out that HBeAg serological conversion is usually achieved in the IHC population in the absence of antiviral treatment, indicating that such patients are in good immune status and more likely to achieve clinical cure, as confirmed by data from several studies. Therefore, how to seize the best time for treatment, optimize the cure pathway and summarize and promote the cure experience is an important issue that needs to be addressed for the benefit of the country and the people.
Professor Lin Bingliang, The Third Hospital of Sun Yat-sen University Professor Lin Bingliang of the Third Affiliated Hospital of Sun Yat-sen University cites data from several studies to explore cure strategies for the IHC population. Several studies have confirmed the use of pegylated interferon alpha to treat patients with IHC to achieve high clinical cure rates. A recent meta-study by Professor Chen Yueyue's team at Beijing Youan Hospital, Capital Medical University, found that IHC patients with HBsAg clearance rates of up to 47% after 48 weeks of pegylated interferon alpha treatment were significantly more effective than those with slow hepatitis B. "The study also found that the HBsAg clearance rate continued to show an increasing trend at 24 weeks of follow-up after discontinuation of the drug, and that an appropriate extension of treatment was beneficial to improve HBsAg clearance." Professor Bingliang Lin said, "The HBsAg clearance rate at 96 weeks is higher than that at 48 weeks in the pegylated interferon alpha-treated IHC population, but it is still worth exploring in depth which groups are more suitable for extended treatment." 15,000 IHC patients to be included in "STARHB Project" Helping more patients achieve clinical cures
Li Mingyang, Director, the China Liver Health At the meeting, Li Mingyang, Director of the China Liver health, said that the "STARHB Project" plans to set up more than 200 project hospitals nationwide and enroll 15,000 IHC patients within two years to help more hepatitis B patients achieve clinical cure. By accumulating evidence-based data from large samples, the program will explore and optimize the treatment pathway for IHC patients, improve the clinical cure rate, reduce the risk of cirrhosis and liver cancer associated with slow hepatitis B, better and more benefit hepatitis B patients, and achieve the goal of clinical cure for hepatitis B.
Professor Wei Lai, China Liver Health Beijing Tsinghua Changgung Hospital Professor Wei Lai, Vice President of Beijing Tsinghua Changgung Hospital, said that the "STARHB Project" is led by Professor Chen Yueyue of Beijing Youan Hospital, affiliated to Capital Medical University, and Professor Gao Zhiliang of the Third Hospital of Sun Yat-sen University, and organises many hospitals across China to explore and research the elimination of hepatitis B, a public health hazard of viral hepatitis. The project will train and bring together a young team to make a cure for chronic hepatitis B and the elimination of viral hepatitis harm an achievable goal, contributing to the health of the next generation.
Professor Chen Yuexin, Beijing Youan Hospital, Capital Medical University
Professor Gao Zhiliang, The Third Hospital of Sun Yat-sen University Professor Chen Yueyue of Beijing Youan Hospital, affiliated to Capital Medical University, announced the list of members of the Starlight Project project management body and made detailed plans for the project, while Professor Gao Zhiliang of the Third Hospital of Sun Yat- sen University read out the list of project hospitals and the 2022 promotion plan. The project has already approved 262 project hospitals, including 38 co-base hospitals and 224 co-sub-center hospitals, covering 28 provinces (autonomous regions and municipalities directly under the Central Government) except for Hong Kong, Macao and Taiwan. In his speech, Mr. Sun Li, Chairman of Xiamen Tebao Bioengineering Co., Ltd, said that it is important to be a good supporter of optimizing the clinical cure for chronic hepatitis B and to help more chronic hepatitis B patients to realize their dream of clinical cure. The project plan and implementation were then further explained and coached by Dr Ren Shan, Deputy Chief Physician of Beijing Youan Hospital, affiliated to Capital Medical University, Dr Zhang Shaoquan, Deputy Chief Physician of the Third Affiliated Hospital of Sun Yat-sen University, and Kotuo Information Technology Co. Summary The inactive HBeAg-negative chronic HBV-infected population is often neglected clinically, while data from several studies show that this group has an unsafe long-term prognosis and a higher chance of clinical cure. How to grasp the optimal timing of treatment, optimize the pathway to cure, and summarize and disseminate cure experience is a scientific challenge that needs to be addressed. Over the past 10 years, Chinese experts have been at the forefront of the quest for a clinical cure for chronic hepatitis B. They have achieved remarkable results in a number of large-scale clinical practices. The "Hepatitis B Clinical Cure Starlight Project" is the first national clinical study for inactive HBeAg-negative HBV-infected patients. It is believed that with the joint efforts of many clinical experts in China, it will bring a new hope of clinical cure for the large group of chronic HBV-infected patients with IHC and help the prevention and control of hepatitis B in China. The development of hepatitis B prevention and control in China! |
关注官方微信 
